Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

Conditions

• Post-aggressive Immunosuppression
• Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6
• Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C

Interventions

• DRUG: Interferon Gamma 1-b
• DRUG: Placebo

Sponsor

Assistance Publique - Hôpitaux de Paris